Aesica Introduces Aseptic Micro Dosing Capabilities at Nottingham Site
Aesica, a global contract development and manufacturing organisation (CDMO), has introduced 3P’s Fill2Weight dispensing system — suitable for all powder formulations including spray dried and lyophilised powders — to its Nottingham site, enabling increased flexibility and reduced time in 'first in human' clinical studies.
The Fill2Weight system is widely acknowledged as the most flexible micro dosing system available to the market, with the technology able to dose a wide range of powders and can quickly be scaled up from clinical to commercial production.
Aesica will be offering the system to customers as a tool that enables the direct filling of APIs in to capsules, syringes or bottles, eliminating the time and cost associated with developing a blended formulation.
Developed to fill a target weight, rather than dispensing fixed volume, Fill2Weight dynamically measures and records the dispensed weight of all doses, allowing for compensation in powder property changes without the need for intervention or re-calibration.
The flexibility offered by the platform means that the micro dosing system can be used across capsules, vials, blisters, injectables or inhalers and weighting resolutions as low as 10 µg (10x lower than the market leading competitor). Consequently, Fill2Weight is usable with potent compounds.
With the increased drive from clients and regulatory bodies for Quality by Design (QbD), the micro dosing system’s flexibility and repeatability ensures that experiments can be designed from laboratory scale right through to commercial supply, thanks to the platform’s modular design. Moreover, multi-track production settings limit process changes in the final stages of product development and provide tighter regulation of process controls. Quality is enhanced with reduced weight variability, lower rejection levels and 100% weight recording, meaning the system is suitable for real-time release, monitoring and recording. The system is configurable for 2.5–500 mg doses, with a dosing accuracy of <3% RSD and cycle feed times of less than two seconds.
The 3P Fill2Weight can be fully sterilised which allows it to be used to aseptically fill re-constitutable powders in to bottles or syringes. This delivers a cost-effective, truly scalable alternative to “in-vial” lyophilisation.
A key benefit of working with the Nottingham site has been its ability to develop clinical trial products rapidly and the system will allow for even great reductions in time to market, with the ultimate impact of reduce the costs of development incurred by customers.
Ian Lafferty, Site Director- Aesica, Nottingham, commented: “Increasingly clients are coming to our Nottingham site with the knowledge that we have the capabilities to develop virtually any dosage form and delivery mechanism. It is this flexibility and, crucially, the speed with which we can develop these products that has proved the main driver of our growth. The Fill2Weight system is widely regarded as the best-in-market micro dosing system. Indeed, its delivery flexibility, reproducibility and scale-up variability makes it the ideal complement to existing services. Ultimately, our goal is to get our clients to “first-in-human” solutions as quickly as possible, reducing time consuming and expensive development work”.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance